Important Safety InformationRyzumvi™ (phentolamine ophthalmic solution) 0.75%Prescribing Information

Now
Approved

To be available
first half of 2024

The FDA has approved
RYZUMVI (phentolamine ophthalmic solution) for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents.

See Press Release

Now
Approved

To be available first half of 2024

The FDA has approved
RYZUMVI (phentolamine ophthalmic solution) for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents.

See Press Release
See full ISI

Important Safety Information

Warnings and Precautions

  • Uveitis: RYZUMVI is not recommended to be used in patients with active ocular inflammation (e.g., iritis).
  • Potential for Eye Injury or Contamination: To avoid the potential for eye injury or contamination, care should be taken to avoid touching the vial tip to the eye or to any other surface.

Indication

RYZUMVI™ (phentolamine ophthalmic solution) 0.75% is indicated for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents.

Important Safety Information

Warnings and Precautions

  • Uveitis: RYZUMVI is not recommended to be used in patients with active ocular inflammation (e.g., iritis).
  • Potential for Eye Injury or Contamination: To avoid the potential for eye injury or contamination, care should be taken to avoid touching the vial tip to the eye or to any other surface.
  • Use with Contact Lenses: Contact lens wearers should be advised to remove their lenses prior to the instillation of RYZUMVI and wait 10 minutes after dosing before reinserting their contact lenses.

Adverse Reactions

The most common adverse reactions that have been reported are instillation site discomfort (16%), conjunctival hyperemia (12%), and dysgeusia (6%).

Click here for full Prescribing Information.

Reference

  • 1. RYZUMVI (phentolamine ophthalmic solution). Prescribing Information. Ocuphire; 2023.
Go to Viatris.com

This site is intended for US healthcare professionals only.

© 2023 Viatris Inc. and/or its affiliates. All rights reserved.

VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris Company.

Oyster Point® and the Oyster Point logo are registered trademarks of Oyster Point, Inc., a Viatris, Inc. Company. RYZUMVI and the RYZUMVI logo are trademarks of Ocuphire Pharma Inc., used with permission.

Oyster Point Pharma, Inc.
Princeton, New Jersey

OP-MYD-002584 9/23